Samuel Dozier, MD
Internal Medicine · Florence, SCNPI 1043283039
Payments from drug & device makers
Across 206 payments — averaging $16.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$493
- Amgen$226
- AbbVie$225
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$203
- Sumitomo Pharma America, Inc.$185
- Esperion Therapeutics, Inc.$168
- plus $2K from 34 others
What the payments were for
- Food & beverage$3,303100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $493 |
| Amgen | 15 | $226 |
| AbbVie | 13 | $225 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $203 |
| Sumitomo Pharma America, Inc. | 8 | $185 |
| Esperion Therapeutics, Inc. | 10 | $168 |
| Amarin Pharma, Inc. | 11 | $158 |
| Abbott | 10 | $156 |
| Novartis | 9 | $148 |
| Merck | 10 | $130 |
| Pfizer | 7 | $106 |
| Sanofi-aventis U.S. LLC | 8 | $105 |
| Eisai Inc. | 7 | $101 |
| GSK | 6 | $97 |
| Lilly USA, LLC | 6 | $88 |
| Exact Sciences | 3 | $52 |
| AstraZeneca | 3 | $51 |
| Boston Scientific | 3 | $51 |
| Axsome Therapeutics, Inc. | 3 | $50 |
| Corcept Therapeutics | 2 | $42 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $42 |
| Radius Health, Inc. | 2 | $38 |
| Cvrx, Inc. | 2 | $38 |
| Dexcom, Inc. | 2 | $37 |
| Johnson & Johnson | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Astellas Pharma US Inc | 2 | $31 |
| Shield Therapeutics Inc | 2 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Bayer | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $15 |
| Renalytix AI, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$3,303 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 177 | $142,515 |
| OzempicSemaglutide | 25 | $32,158 |
| JardianceEmpagliflozin | 28 | $27,035 |
| TrulicityDulaglutide | 22 | $26,524 |
| FarxigaDapagliflozin Propanediol | 31 | $22,487 |
| JanuviaSitagliptin Phosphate | 23 | $17,738 |
| MounjaroTirzepatide | 14 | $14,326 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $13,097 |
| MyrbetriqMirabegron | 14 | $11,835 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 38 | $11,668 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $11,597 |
| Praluent PenAlirocumab | 16 | $7,498 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $7,347 |
| EntrestoSacubitril/Valsartan | 11 | $6,954 |
| Ezetimibe | 168 | $6,773 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $106 | $148,363195 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $88 | $40,85036 claims |
| Boehringer IngelheimJardiance, Tradjenta | $14 | $32,93540 claims |
| Novo NordiskOzempic | $493 | $32,15825 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $97 | $30,01784 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $51 | $29,83542 claims |
| MerckJanuvia | $130 | $17,73823 claims |
| Astellas Pharma US IncMyrbetriq | $31 | $11,83514 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $105 | $11,59715 claims |
| NovartisEntresto | $148 | $6,95411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Florence
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
- Jerry BackNorth Charleston$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.